148 related articles for article (PubMed ID: 37725810)
21. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
[TBL] [Abstract][Full Text] [Related]
22. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P
Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae.
Pérez-Nadales E; Fernández-Ruiz M; Natera AM; Gutiérrez-Gutiérrez B; Mularoni A; Russelli G; Pierrotti LC; Pinheiro Freire M; Falcone M; Tiseo G; Tumbarello M; Raffaelli F; Abdala E; Bodro M; Gervasi E; Fariñas MC; Seminari EM; Castón JJ; Marín-Sanz JA; Gálvez-Soto V; Rana MM; Loeches B; Martín-Dávila P; Pascual Á; Rodríguez-Baño J; Aguado JM; Martínez-Martínez L; Torre-Cisneros J;
Am J Transplant; 2023 Jul; 23(7):1022-1034. PubMed ID: 37028515
[TBL] [Abstract][Full Text] [Related]
25. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
Kong W; Yang X; Shu Y; Li S; Song B; Yang K
Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of
Drusano GL; Shields RK; Mtchedlidze N; Nguyen MH; Clancy CJ; Vicciarelli M; Louie A
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160285
[TBL] [Abstract][Full Text] [Related]
28. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
[TBL] [Abstract][Full Text] [Related]
29. Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients.
Gaibani P; Bovo F; Bussini L; Bartoletti M; Lazzarotto T; Viale P; Pea F; Ambretti S
Clin Microbiol Infect; 2023 May; 29(5):654.e1-654.e4. PubMed ID: 36716999
[TBL] [Abstract][Full Text] [Related]
30. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
Gu J; Xu J; Zuo TT; Chen YB
J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
[TBL] [Abstract][Full Text] [Related]
31. Carbapenem-resistant Klebsiella pneumoniae outbreak with monoclonal spread: Evaluation of resistance genes and ceftazidime-avibactam susceptibility.
Arıcı N; Tanrıverdi ES; Çalık Ş; Kansak N; Adaleti R; Otlu B; Aksaray S
Indian J Med Microbiol; 2023; 46():100431. PubMed ID: 37945124
[TBL] [Abstract][Full Text] [Related]
32. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
[TBL] [Abstract][Full Text] [Related]
34. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
[TBL] [Abstract][Full Text] [Related]
35. Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China.
Xu M; Zhao J; Xu L; Yang Q; Xu H; Kong H; Zhou J; Fu Y
Clin Microbiol Infect; 2022 Jan; 28(1):136.e1-136.e6. PubMed ID: 34044150
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.
Chen W; Sun L; Guo L; Cao B; Liu Y; Zhao L; Lu B; Li B; Chen J; Wang C
Ann Transl Med; 2020 Feb; 8(3):39. PubMed ID: 32154284
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
[No Abstract] [Full Text] [Related]
38.
Li X; Chen Z; Jiao J; Wang S; Wang Y; Wu W; Yang H; Lou H
Expert Rev Anti Infect Ther; 2023 Jan; 21(1):91-98. PubMed ID: 36433637
[TBL] [Abstract][Full Text] [Related]
39. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
Qu J; Xu J; Liu Y; Hu C; Zhong C; Lv X
Int J Antimicrob Agents; 2023 Aug; 62(2):106872. PubMed ID: 37247645
[TBL] [Abstract][Full Text] [Related]
40. Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant
Li D; Liao W; Huang HH; Du FL; Wei DD; Mei YF; Long D; Wan LG; Liu Y; Zhang W
Infect Drug Resist; 2020; 13():2673-2680. PubMed ID: 32821131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
